Tetsuro Taki

10PUBLICATIONS
127CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Te hauora me te oranga o te Māori kāore anō kia whakarōpūhia i wāhi kē (Māori health and wellbeing not elsewhere classified)Liquid biopsiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 30, 2026
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study.

|Nov 18, 2024
NETosis in pulmonary pleomorphic carcinoma.

Hajime Oi, Tetsuro Taki, Takashi Kuroe

|Oct 25, 2024
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).

Keiju Aokage, Shohei Koyama, Shogo Kumagai

|Jun 07, 2024
Response to Wu and Zhang.

Tetsuro Taki, Genichiro Ishii

Pageof 2